Traders should monitor enrollment completion in mid-2026 and eGFR slope data in Q2 2027 as key catalysts. While reduced losses and strong cash position de-risk near-term execution, absence of revenue and continued net losses limit bullishness. Positive clinical momentum supports long-term upside, but stock remains binary on Phase 3 outcomes.
Price Chart
Executive Summary
ProKidney reported financial results for 2025, highlighting a reduction in net loss to $151.6 million from $163.3 million in 2024, driven by lower R&D and G&A expenses. The company maintains a strong clinical trajectory with FDA alignment on an accelerated approval pathway for rilparencel based on eGFR slope, and completed enrollment in its Phase 3 PROACT 1 trial is expected by mid-2026, with pivotal data readout anticipated in Q2 2027. Cash reserves totaled $270.0 million at year-end, sufficient to fund operations into mid-2027.
Key Financial Metrics
Key Facts
- Net loss before noncontrolling interest decreased to $151.6 million in 2025 from $163.3 million in 2024.
- R&D expenses declined to $114.1 million (from $127.7M) due to completion of prior trials, partially offset by increased costs in the ongoing PROACT 1 study.
- G&A expenses fell to $51.8 million (from $56.1M), driven by lower impairment and equity compensation charges.
- Cash, cash equivalents, and marketable securities totaled $270.0 million as of December 31, 2025, down from $358.3 million in 2024.
- Company reaffirmed cash runway into mid-2027, aligning with Phase 3 trial milestones.
- FDA confirmed eGFR slope as a valid surrogate endpoint for accelerated approval of rilparencel in a July 2025 Type B meeting.
- Phase 3 PROACT 1 enrollment on track for completion in mid-2026, with topline data expected Q2 2027.
Financial Impact
Reduced annual cash burn by ~$11.7 million year-over-year; ending cash balance of $270.0 million supports operations into mid-2027.
Risk Factors
- Clinical trial results may not meet expectations, particularly the eGFR slope endpoint in 2027.
- Regulatory risk: FDA may require additional data beyond the accelerated pathway despite current alignment.
- Cash runway estimate assumes no delays or cost overruns; any setback could necessitate earlier dilutive financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258574 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $1.61 $1.85 | ▲ +14.91% | ▲ +15.97% | $1.71 (+5.90%) |
Aug 10, 2026 7w ago | Press Release | $1.61 $1.85 | ▲ +14.91% | ▲ +15.97% | $1.71 (+5.90%) |
May 15, 2026 20w ago | 8-K | $1.66 $1.67 | ▲ +0.60% | ▼ −1.52% | $1.71 (+2.71%) |
May 15, 2026 20w ago | Press Release | $1.66 $1.67 | ▲ +0.60% | ▼ −1.52% | $1.71 (+2.71%) |
Apr 17, 2026 23w ago | DEFA14A | $2.10 $1.61 | ▼ −23.33% | ▼ −27.54% | $1.71 (−18.81%) |
Mar 18, 2026 28w ago | Press Release | $1.95 $2.18 | ▲ +11.79% | ▲ +4.17% | $1.71 (−12.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access